Target intelligence / Profile preview

MicroRNA 4323 (MIR4323)

Target
MIR4323
Molecular classification
MicroRNA (miRNA), Non-coding RNA
01

Overview

MicroRNA 4323 (MIR4323) is a member of the human microRNA family; it is a short, non-coding RNA molecule (~20–24 nucleotides) that regulates gene expression by targeting messenger RNAs for translational repression or degradation. MIR4323 was found to promote human bladder smooth muscle cell proliferation under cyclic hydrodynamic pressure by inhibiting the expression of LYN kinase, which in turn activates the Erk1/2 (MAPK) signaling pathway, a central regulator of cell proliferation and differentiation. While MIR4323's direct involvement in disease is still emerging, its ability to modulate cell proliferation suggests potential relevance in pathological tissue remodeling or cancer biology, though no clinically approved drugs directly target MIR4323 at present.

Other names
hsa-mir-4323MIR4323
02

Mechanism of action

Downregulation of target gene LYN kinase via binding to its mRNA; Activation of Erk1/2 (MAPK) signaling pathway by inhibiting LYN, leading to enhanced smooth muscle cell proliferation under hydrodynamic pressure

03

Biological functions

Post-transcriptional regulation of gene expressionCell proliferation, especially in bladder smooth muscle cells under stress conditionsModulation of signaling pathways (mainly Erk1/2/MAPK)
04

Disease associations

Bladder function and potentially related disorders due to effects on smooth muscle cell proliferationAssociated with Alternating Esotropia, though molecular links are not extensively documentedOther roles are possible through miRNA’s general impact on cell cycle regulation, but disease association for MIR4323 is currently limited
05

Safety considerations

None documented specifically for MIR4323General safety concerns for miRNA-based therapy include unintended off-target effects due to pleiotropic regulation, immune activation, and delivery challenges
06

Interacting drugs

None reported specifically for MIR4323; miRNAs in general may be modulated by nucleic acid-based therapeutics, but no direct small molecule or biologic drugs are known for this particular microRNA
07

Biomarkers

No validated biomarkers for MIR4323 in clinical useExperimental upregulation can indicate elevated cell proliferation in bladder smooth muscle, suggesting potential for future biomarker development

Beyond the preview

Go deeper on MicroRNA 4323 (MIR4323).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 4323 (MIR4323).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call